Camp4 Therapeutics Poration Stock Performance
| CAMP Stock | USD 1.81 0.11 5.73% |
CAMP4 THERAPEUTICS has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.11, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CAMP4 THERAPEUTICS are expected to decrease at a much lower rate. During the bear market, CAMP4 THERAPEUTICS is likely to outperform the market. CAMP4 THERAPEUTICS at this time shows a risk of 5.75%. Please confirm CAMP4 THERAPEUTICS downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if CAMP4 THERAPEUTICS will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CAMP4 THERAPEUTICS PORATION are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent primary indicators, CAMP4 THERAPEUTICS may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
| Begin Period Cash Flow | 40 M | |
| Total Cashflows From Investing Activities | -441 K |
CAMP4 THERAPEUTICS Relative Risk vs. Return Landscape
If you would invest 185.00 in CAMP4 THERAPEUTICS PORATION on April 27, 2025 and sell it today you would lose (4.00) from holding CAMP4 THERAPEUTICS PORATION or give up 2.16% of portfolio value over 90 days. CAMP4 THERAPEUTICS PORATION is currently generating 0.1217% in daily expected returns and assumes 5.7499% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than CAMP4, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CAMP4 THERAPEUTICS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CAMP4 THERAPEUTICS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CAMP4 THERAPEUTICS PORATION, and traders can use it to determine the average amount a CAMP4 THERAPEUTICS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0212
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | CAMP | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.75 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average CAMP4 THERAPEUTICS is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CAMP4 THERAPEUTICS by adding it to a well-diversified portfolio.
CAMP4 THERAPEUTICS Fundamentals Growth
CAMP4 Stock prices reflect investors' perceptions of the future prospects and financial health of CAMP4 THERAPEUTICS, and CAMP4 THERAPEUTICS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CAMP4 Stock performance.
| Current Valuation | 109.74 M | ||||
| Shares Outstanding | 20.16 M | ||||
| Price To Earning | 318.57 X | ||||
| Revenue | 652 K | ||||
| EBITDA | (51.39 M) | ||||
| Cash And Equivalents | 47.72 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 8.65 M | ||||
| Book Value Per Share | (158.04) X | ||||
| Cash Flow From Operations | (45.56 M) | ||||
| Earnings Per Share | (2.64) X | ||||
| Total Asset | 78.31 M | ||||
| Retained Earnings | (211.75 M) | ||||
| Current Asset | 298.77 M | ||||
| Current Liabilities | 49.56 M | ||||
About CAMP4 THERAPEUTICS Performance
Assessing CAMP4 THERAPEUTICS's fundamental ratios provides investors with valuable insights into CAMP4 THERAPEUTICS's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the CAMP4 THERAPEUTICS is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company was incorporated in 1981 and is headquartered in Irvine, California. CalAmp Corp operates under Communication Equipment classification in the United States and is traded on NASDAQ Exchange. It employs 887 people.Things to note about CAMP4 THERAPEUTICS performance evaluation
Checking the ongoing alerts about CAMP4 THERAPEUTICS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CAMP4 THERAPEUTICS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CAMP4 THERAPEUTICS had very high historical volatility over the last 90 days | |
| CAMP4 THERAPEUTICS may become a speculative penny stock | |
| The company reported the previous year's revenue of 652 K. Net Loss for the year was (51.79 M) with loss before overhead, payroll, taxes, and interest of (37.93 M). | |
| CAMP4 THERAPEUTICS PORATION currently holds about 47.72 M in cash with (45.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies |
- Analyzing CAMP4 THERAPEUTICS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CAMP4 THERAPEUTICS's stock is overvalued or undervalued compared to its peers.
- Examining CAMP4 THERAPEUTICS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CAMP4 THERAPEUTICS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CAMP4 THERAPEUTICS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CAMP4 THERAPEUTICS's stock. These opinions can provide insight into CAMP4 THERAPEUTICS's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CAMP4 Stock Analysis
When running CAMP4 THERAPEUTICS's price analysis, check to measure CAMP4 THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CAMP4 THERAPEUTICS is operating at the current time. Most of CAMP4 THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of CAMP4 THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CAMP4 THERAPEUTICS's price. Additionally, you may evaluate how the addition of CAMP4 THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.